» Articles » PMID: 30214181

COPD Uncovered: a Cross-sectional Study to Assess the Socioeconomic Burden of COPD in Japan

Overview
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2018 Sep 15
PMID 30214181
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: COPD remains a major health problem in Japan. Patients with COPD experience a reduced quality of life (QoL) and have a higher chance of work impairment and productivity loss. However, there is a lack of data on the impact of COPD in terms of QoL and work activity impairment in Japan. This study assessed the socioeconomic burden of COPD in Japan and the impact it may have on the working age population.

Patients And Methods: This was a 2-year retrospective chart review in COPD patients aged ≥40 years, with at least one health care visit to clinic or hospital in the previous 12 months. Patients were required to have available medical charts for at least the previous 24 months. Symptoms were assessed using COPD assessment test score; EuroQoL Group 5 Dimension (EQ-5D-5L) and work productivity and activity impairment general health questionnaires were used to evaluate health-related QoL and work productivity, and health care resource utilization data were obtained from clinical charts.

Results: In total, 71 patients aged <65 years, and 151 patients aged ≥65 years were included; the majority of patients had moderate or severe airflow limitation. Exacerbations (moderate or severe) were reported by ~35% of patients in both age groups; 52.1% and 62.9% of patients in the <65-year and ≥65-year age groups had COPD assessment test scores ≥10. EQ-5D-5L index scores in the <65-year and ≥65-year age groups were 0.79 and 0.77, respectively. Work productivity and activity impairment scores were higher in <65-year age group. Annual costs of health care resource use per patient in the <65-year and ≥65-year age groups were ¥438,975 (US$4,389) and ¥467,871 (US$4,678), respectively. Costs due to productivity loss were estimated to be ¥5,287,024 (US$52,870) in the <65-year age group and ¥3,018,974 (US$30,187) in the ≥65-year age group.

Conclusion: COPD represents a significant socioeconomic burden in Japan. Patients with COPD report significant use of health care resources. Higher impact on work impairment and productivity loss was observed frequently in the working age population.

Citing Articles

Poor treatment outcomes of acute exacerbations of chronic obstructive pulmonary disease and their associated factors among admitted patients in East Gojjam, 2023.

Getnet M, Afenigus A, Gete M, Emrie A, Tsegaye D Front Med (Lausanne). 2024; 11:1434166.

PMID: 39635589 PMC: 11615673. DOI: 10.3389/fmed.2024.1434166.


Assessment of Health-Related Quality of Life Among Patients with Chronic Diseases and Its Relationship with Multimorbidity: A Cross-Sectional Study from Saudi Arabia.

Alzarea A, Khan Y, Alzarea S, Alanazi A, Alsaidan O, Alrowily M Patient Prefer Adherence. 2024; 18:1077-1094.

PMID: 38854480 PMC: 11162240. DOI: 10.2147/PPA.S448915.


Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study.

Czira A, Akiyama S, Ishii T, Wood R, Camidge L, Wallis H Int J Chron Obstruct Pulmon Dis. 2023; 18:2933-2953.

PMID: 38089540 PMC: 10715027. DOI: 10.2147/COPD.S419119.


Factors associated with health-related quality of life among employed individuals with chronic obstructive pulmonary disease: A correlational study in China.

Zhang P, Samartkit N, Masingboon K Belitung Nurs J. 2023; 9(3):271-279.

PMID: 37492761 PMC: 10363970. DOI: 10.33546/bnj.2654.


Factors affecting work productivity and activity impairment among chronic obstructive pulmonary disease patients.

Abdelwahab H, Sehsah R, El-Gilany A, Shehta M Ind Health. 2023; 62(1):20-31.

PMID: 37081622 PMC: 10865086. DOI: 10.2486/indhealth.2022-0174.


References
1.
Vos T, Flaxman A, Naghavi M, Lozano R, Michaud C, Ezzati M . Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2163-96. PMC: 6350784. DOI: 10.1016/S0140-6736(12)61729-2. View

2.
Souliotis K, Kousoulakou H, Hillas G, Tzanakis N, Toumbis M, Vassilakopoulos T . The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2017; 12:1395-1400. PMC: 5436756. DOI: 10.2147/COPD.S132825. View

3.
Minakata Y, Ichinose M . [Epidemiology of COPD in Japan]. Nihon Rinsho. 2011; 69(10):1721-6. View

4.
Patel J, Nagar S, Dalal A . Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis. 2014; 9:289-300. PMC: 3964024. DOI: 10.2147/COPD.S57157. View

5.
Reilly M, Zbrozek A, Dukes E . The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993; 4(5):353-65. DOI: 10.2165/00019053-199304050-00006. View